This Program Project Grant evaluates the role of dose-intensification in the treatment of breast and ovarian cancer. We propose to use high dose combination alkylating agents and bone marrow support in the treatment of early metastatic breast cancer following induction chemotherapy with adriamycin and to use high dose chemotherapy and bone marrow support in high risk Stage II Breast cancer involving 10 or more lymph nodes and high dose systemic cyclophosphamide and thiotepa with bone marrow support and to perform phase I and phase II trials of high dose therapy and autologous bone marrow support in ovarian cancer. Using multiple monoclonal antibodies, we will monitor bone marrow for involvement with malignant breast cancer cells and develop immunopharmacologic methods for removing the malignant contamination. Two projects will attempt to ameliorate the toxicity of high dose chemotherapy. We will extend our initial observations using recombinant granulocyte macrophage colony-stimulating-factor (rHuGM-CSF) in shortening the period of myelosuppression following high dose therapy and autologous bone marrow support by performing a randomized, comparative trial. We will perform investigations to understand the mechanism underlying refractory and dysfunctional thrombocytopenia and evaluate the therapeutic approaches. The performance of these projects is supported by three core projects, involving cryopreservation, statistics and administration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047741-02
Application #
3094248
Study Section
Special Emphasis Panel (SRC (P1))
Project Start
1990-06-01
Project End
1993-05-31
Budget Start
1991-06-01
Budget End
1992-05-31
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Brennan, Todd V; Lin, Liwen; Huang, Xiaopei et al. (2018) Generation of Luciferase-expressing Tumor Cell Lines. Bio Protoc 8:
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
MacDonald, Kelli Pa; Blazar, Bruce R; Hill, Geoffrey R (2017) Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 127:2452-2463
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
MacDonald, Kelli P A; Hill, Geoffrey R; Blazar, Bruce R (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129:13-21
Du, Jing; Paz, Katelyn; Flynn, Ryan et al. (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood 129:2570-2580
Rowland, Christopher R; Colucci, Lina A; Guilak, Farshid (2016) Fabrication of anatomically-shaped cartilage constructs using decellularized cartilage-derived matrix scaffolds. Biomaterials 91:57-72
Flynn, Ryan; Paz, Katelyn; Du, Jing et al. (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127:2144-54
Brennan, Todd V; Lin, Liwen; Brandstadter, Joshua D et al. (2016) Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest 126:207-19
Sung, Anthony D; Sung, Julia A M; Thomas, Samantha et al. (2016) Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 63:999-1006

Showing the most recent 10 out of 132 publications